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Objectives. The aim of this study was to examine whether cyclic 
goonwine monophosphate (GMP) may he involved in the onti- 
thmmbotic octioa of nitroglycerin. 
Bockground. Nitroglycsrin has be31 shorn !C k&i&~ plot&t 
lonelion io vitro by stimulating prostacyclin or inhibitin: throm. 
boxane AZ production, or both. Nitmglycerin has nlsa been shown 
to pa%f%s potent antithrombntic properties in viva. However. the 
mecbantsm of this anttthmmtmtic &feet ts unetear. 
&fekis. Nitroglycerin was infused to produce a IO% decrease 
in mean arterial pressure in 27 normal pigs by exposing their 
cireulrting arterial blood to porcine aortic media in en ex viva 
perfusion chamber. Eight pigs received an infusion of nitrogtyc. 
erin alone; eight rweived an infusion of methyteoe blue, a
guanylste yck irddbitor, followed by nitroglycerin infusion a d 
Rve fgs received an infusion of nitvog?ycerin fottoned by rnethyt- 
ene blue and subsoquerd infuston oi cyclic GMP. 
Resrdfs. With nitroglycerin &me. quantitative autolngous 
indium.lll-labeled platelet deposition (~10~) on the axtic 
media was deereased to 63.9 + 10.4% ID = 0.01) of lk ti 
tine control ptaietet depositton. Methy& blue givea b&we 
nitroglycerin tended to inore= platelet deposit& relative 
to bnseline and platelet deposition after nitroglycerin was 
142 2 35% (p = NS) of basdine value. lo pigs that received 
all three agents, nltrogtyeerin r&wed ptatelet depasittou to 
42.3 5 t2.2% of bus&w v&w: this deerew was the0 attenuated 
by subsequent mcthylene blue iotsiw but aia( by 
cyclic GMP infusios to 16.4 ? 3.8% of box&e v&e (p = 
O.W6 vs. bnsetine mntmt and p = 0.02 W~SUS rootbykw Mw 
infusianL 
Corrclusions. Guan$atc cyctase tibitioa with mcthy:ene blue 
abolishes the antithmmbotic effwt of nitrogtyceti, whkh (M be 
enhanced by qctii GMP. 
(J Am Cd Car&d 1993;20:255-9) 
Organic nitrates have been used to prevent and treat myo- 
cardial ischemia for more than a century. Nitroglycerin‘s 
proved clinical efficacy is believed to be due to vasodilation 
of both the coronary and the petipheral \~osculur beds 
(I-5). In addition, nitroglycerin has been rhnwn to inhibit 
platelet aggregation in vitro M-8). although this effect 
is observed at concentrations that are not achievable in 
viva in humans (7). Recently, however. we demonstrated 
(9) that nitroglycerin infused IO decrease mean arterial 
pressure by 10%. as it is given in patients, causes a signift- 
cant decease in platelet mural thrombus deposition and 
the associated vavoconstriction related to arteria! injury in 
the intact animal. These data suggested that nitrog!ycerin 
mey inhibit the platelet&arterial wall Lnteraclion in viva 
and may decrease injury-related vasoconswiction by inbib- 
iting platelet-dependent vasoconstriction as well as by a 
direct effect on the arterial smooth muscle (9.10). Subse- 
quently. we demonstrated (111 in humans that nitroglycerin 
infused tu iower mean arterial pressure by IO% is associated 
with significnnr plntelet inhibition. 
The mechanism by which nitroglycerin inhibits this 
platele:-arterial wall interaction in vivo is not clear. In 
vitro. at supraphysiologic concentrations. it appears that 
the inhibition of platelet interaction by nitroglycerin is 
mediated by stiinularion of prostacyclin or inhibition of 
thromboxane A,. or both (6-g). However, at nitroglycerin 
concentrations that are clinically relevant, the beneficial 
effects of nitrates do not appear to be mediated by an 
increased prostacyclin production (12.13). More reccztly. 
in a dog model of stenosed canine coronary arteries. it 
was shown (14) that cyclic blood flow responses due to 
platelet aggregation and dislodgment can be inhibited by 
clinically achievable nitroglycerin concentration in viva, 
and lhat this may be mediated by cyclic guanosine mono- 
phosphate (CMP). 
To investigate whether cyclic GMP may be involved 
in the inhibition by nitroglycerin of platelet-mural 
rhrombus deposition on deeply injured vessel wall ex- 
posmg the media (9). we examined the effects of niiro- 
glycerin on quantitative platelet deposition onto aortic 
media in the presence or absence of methylene blue, a 
guanylaie cyclase inhibitor, and the administration of 
cyclic GMP. 
30 mm long) was removed, resulting in a window permitting 
direct exposure of Rowing blood to a piece of exposed 
arterial media held in place by the pressure of the upper lid 
and secured together by a surrounding chamber holder. 
Aortie media. Aortas harvested from normal pigs were 
stored in TrIs HCI 0.1 mol buffer, pH 1.4 with antibiotics 
(penicillin and streptomycin), and used within 4 days of 
harvesting as previously described (15-17). Before the ex- 
periment, the aorta was prepared by removing the loose 
adventi’ia. The intima and subjacent media were then re- 
moved by peeling off from one corner of the longitudinally 
opened aorta and discarded. This injury to the vessel wall 
provided a thrombogenic media adjacent to the adventitia 
that was exposed to circulating blood as IS x 35.mm 
sections in the superfusion flow chamber experiments. For 
each experiment only one pig’s aorta was used. 
MdlKldS 
Experimental pmcedure. Normal Yorkshire pigs approx- 
imately 6 weeks of age were anesthetized by an intramuscu- 
lar injection of a mixture of IW mg of ketamine (Ketalar, 
Parke-Davis Canada Inc.) and 80 mg of azaperone (Stresnil, 
Janssen Phanaceutical). A cutdown of the femoral artery 
and vein was then performed with the artery and vein then 
cannulated and connected to superfusion Row chambers 
with silicone tubing, 6 to 10 in. 0.6 to 12 cm) long. Blwd 
was drawn from the femoral artery into the chambers to 
interact with aortic media strips, by means of a peristaltic 
pump (Master&, model 7013) placed distal to the superfu- 
sion Row chambers (15,16). A 5.min superfusion was per- 
formed at a constant blood flow of 20 mllmin through the 
chamber, after which the aortic media was removed and the 
amount of radioactively labeled platelets interacting with the 
media was measured in a gamma counter. Duplicate runs 
throogh the flow chambers were performed for each baseline 
control and drug infusion and the mean counts noted The 
arterial blood pressure was monitored during the experi- 
ment. The experiments were performed in accordance with 
the “Position of the American Heart Association on Re 
search Animal Use.” 
Radllacttve labeling of platelets. Approximately 16 to 
24 h before the superfusion experiments, 43 ml of blood in 
7 ml of acid-citrate dextrose solution was obtained from the 
pig by venipuncture. The blood was centrifuged at 180 g for 
15 min, after which the platelet-rich plasma WBE removed 
and centrifuged at 1,600 g for IO min. The platelet-poor 
plasma was set aside while the platelet-rich pellet was 
resuspended with indium-Ill (“‘In)-trap&me and 2 ml of 
acid-citrate dextrose saline solution at rcan temperature for 
20 minutes. The “‘In-tropolone mixture was prepared by 
mixing 50 M of tropolone (Sigma Chenicals) in normal 
saline solution with 0.5 mCi of “‘In chloride (Amersham). 
After the 20.mitt incubation, the suspension was centriiuged 
for 10 min at I.600 g. The platelet-containing pellet was 
resuspended in 4 ml of platelet-paor plasmr and incubated 
for another 5 min to remove any free unbound “‘In- 
tropolonc. If was again centrifuged for 10 min at I.630 g and 
the labeled platelet pellet was finally resuspaded in 5.5 ml of 
platelet-paw plasma and centrifuged at 100 g for 10 min to 
remove any macroaggregates. The “‘In-labeled platelets 
now contained in the supernatant were removed, and 
counted in an ionization chamber before intravenous rein- 
jection into the pig. The superfusion experiment was per- 
formed 16 to 24 h later, to allow a return to baseline steady 
state conditions after the labeled platelet infusion. 
Superfusion chamber. The superfusion chamber devel- 
oped by L. Badimon (15.16) was designed to mimic the 
lubelike shape of the vascular system. It was made of 
Plexiglas and consisted of an upper lid and a lower block, the 
lower block having a small cylindric hole of I-mm diameter 
bored through it to allow the flow of blood. The surrounding 
upper wall or roof of this cylindric tube (I-mm diameter x 
Qnantitation of platelet deposition. The extent of platelet 
deposition on the aortic media segments was quantitated by 
assessing the eznmt of “‘In-labeled platelets interacting 
with the media. This was obtained by measuring the radio- 
activity in counts per minute (cpm) in each segmect of aortic 
media after correction for radionuclide decay. The radio- 
activity per ml of blwd was also determined at the time of 
the experiment. With knowledge of the whole blood platelet 
count (Coulter counter) obtained from the fcmonl artery, 
the number of platelets deposited on the media was crdcu- 
lated with the following equation: 
No. of dwshed plate& 
(“‘In cpm in amtic media) X (No. of platelets/ml bkmd) 
= 
(“IIn cprnlml blood) 
Mediilion. Nitroglycerin solution (Montreal Heart In- 
stitute Fomwlary) was prepared by crushing and dissolving 
nitroglycerin tablets (Eli Lilly) in 9% dextrose in water, and 
the filtered solution (0.5 me/ml) was infused into an ear vein 
with an intravenous pump (IVAC model 560). The therapeu- 
tic dose of nitroglycerin in pigs is unknown. Because an 
arbitrary dose may not be adequate or optimal in all pigs, and 
because there may be no correlation between the rate of 
nitroglycerin infusion and plasma nitroglycerin concentra- 
tion, nitroglycerin WBE individually titrated to produce a 10% 
decrease in mean arterial pressure. Titration to this hem-z- 
dynamic end point has also beer used to indicate adequacy 
of treatment in severul clinica studies (18) and has been 
shown to be associated with beneficial effects in humans, 
as well as with potent antithromhotic effects in viva in pigs 
(9). In this study, the mean dose of nitroglycerin infused was 
7M) &min. The chamber runs were wrformed in duolicate 
I5 lb j0 min alter the nitroglycerin infusion was stat& 
Plasmh cyclic GMP levels were measured with commer- 
cially available mdioimmunoassay kits (Amersham Intema- 
lion& after extraction by ethanol. Methylene blue (Sigma) 
was prepared at a concentration of 5 x IO-’ m&liter and 
was given as a lo-ml bolus followed by an intravenous 
infusion of 3 mllmin with use of a Harvard pump. Serum 
mcthylene blue level at the time of the supcrfusion capcri- 
mcnt was determined spectrophotometrically. In two series 
of experiments. nitroglycerin was administered before mfu- 
sion of methylene blue: in a third wies. it WP administered 
after the infusion. 
The cyclic GMP analogue. S-hmmo cyclic GMP LSigmal. 
or its vehicle was infused with use of a Harvard pump 
through a side port in the arterial line just before it entered 
the superfusion chamber. The rate of the infusion was 
adjusted to yield a concentration of 7.4 x IO-” mollliter in 
the flow chamber. 
Statistics. All valws are exmessed as mean value 2 SE 
unless otherwise indicated. A&ysis of variances was used 
to perform multiple group comparisons. and intergroup 
analysis was tested by the Fisher protected least significant 
difference test; p values of < 0.05 were considered signifi- 
cant. 
Results 
In these studies. each pig served as at:* own zwdrui. Tnus. 
a baseline control platelet deposition level obtained before 
drug infusion was compared with the subsequent platelet 
deposition obtained after each drug infusion. 
Nitroglycerin infusion. Despite a IO% decrease in mean 
arterial pressure in the pigs. blood Row thruugh the ca viva 
superlusian chamber was maintained constant with the 
peristaltic pump. This procedure was well tolerated by the 
animals. Under these constant Row conditions. platelet 
deposition was 55.5 ? 6.1 x lo6 on the aortic media, and 
intravenous nitroglycerin produced a decrease in platelet 
dew&ion that was 63.9 2 10.4% tn = 8. D = 0.01) of the 
ba&nc control value. In four pi& in whi;h plasm; cyclic 
GMP levels were measured, there was B significant in- 
wcw in cyclic GMP to a mean of 2.109.5 fmotiml (p < 
0.05) after nitroelvcerin infusion. relative to a baseline level 
of 1;76&5 frnoU;;li. 
Mcthykne blue infusion bcforc nitmglyecrin administra- 
lion. In a second group of eight pigs, infusion of the gua- 
nylate cyclase inhibitor. methylene blue, achieving a con- 
centration of 2.1 t 0.4 x IO-’ molllitcr, produced a non- 
significant trend toward an increase in platelet deposition to 
155 f 28% ID = 0.09) of the baseline control value. The 
subsequent ~dministr&n of nitroglycerin intravenously 
caused no significant decrease in platelet deposition. in 
contrast to the previous experiments, and platelet deposition 
was 142 + 3J% of the baseline control vtdue (p = NW (Fig. 
1). 
Nitr@ynrin, mcthylene blue and cyclic C?IIP administra- 
tion. Relative to baseline control, the intravenous infusion 
of nitroglycerin before methylenc blue admiristration in the 
thirdgroup of live pigs again resulted in a decrease in platelet 
deposition (Fig. 2). and confirmed the results dacumensd 
initially. The subsequent infusion of methylene blue attenu- 
ated this c&t of nitioglyceiin with n mild increase in 
platelet deposition, which was now not significantly different 
Figure 1. Nat&t depsition expressed as a percent of the baseline 
coarot level I\ incrcaeaxd after mcthylew blue infusion and rc- 
maned mcrcawd despite subsequent itroglycerin (NT@ infusion. 
p Kd”cl compare drug vcrsur baseline. 
from the baseline control value (Fig. 2). Infusion of the 
cyclic GMP analogue. 8.bmmo cyclic GMP. thereafter rc- 
sultcd in a further significant decrease in platelet deposition 
to 16.4 -r 3.8% of control value (p = 0.W vs. baseline 
control. and p = 0.02 vs. methytene blue iefasion) (Fig. 2). 
These results show that nitroglycerin can decrease plate- 
let thrombus deposition on the exposed media of the injured 
vessel wall. and thus confirm our previous demcnstration of 
its potent antithromhatic property noted in viva (9). Under 
conditions of constant blood flow. nitroglycerin car decrease 
by as much as 57% the amaunt of platelet deposition onto the 
exposed aortic media relative to the baa&c value. This 
antithmmbotic effect of nitroglycerin was associated with a 
significant increase in plasma cyclic GMP levels. Pretreat- 
ment with methykne blue, to inhibit the guanylate cyclase 
cnzync (19). blocked this inhibition of mural platelet- 
Figure 2. Platelet deposition expressed as a percent of baseline 
control is decreased alter nitroglycerin (NTG) infusion. This dc- 
crease is ;attenuated by mcthylcnc blue infusion but cnhanscd by 
aubscquent cyclic guano& monophosphate infusion tcCMPt. 
tion through a prostaglandin mechanism. However, a~ phys- 
iologic concentration and in the presence of blood vessels, 
nw~glyccrin may inhibit the platelet-vessel wall interaction 
through a cyclic GMP mechanism. 
Pretreatment with methykne blue blocked the platelet 
inhibitory effect of nitroglycerin but this effect was only 
attenuated when methylene blue was given after the nitro- 
glycerin infusion. This difference may occur because cyclic 
GMP pr+~Wi~n stimulated by nitroglycerin may produce 
levels thal remain high despite subsequent inhibition of the 
goanylate cyclase enzyme by methylene blue. However, 
guanylate cyclasc inhibition by methylene blue e5cctively 
prevents the stimulation of guanylatc cyclase by nitroglyc- 
erin, as observed in the first and third groups ofanimals. The 
slight increase in platelet deposition after methylene blue 
infusion in group 2 pigs, although not statistically significant, 
perhaps because of rhe small number of animals, raises the 
possibility that the basal secretion of cndogenous nitmglyc- 
erin in the form of cndothelium-derived relaxing factor (24), 
a cyclic GMP modulator, may influence the reactivity of the 
circulating platelets or the thrombogenicity of the vessel 
wall. 
Cliniul implications. The beneficial antithrombotic e5ect 
of nitroglycerin in the presence of a type 3 injury exposing 
the very thrombogenic media, as demonstrated in this study 
at clinically relevant concentrations, may have important 
consequences. Continuous iofusions of intravenous nits 
glycerin are commonly used to treat unstable angina and 
appear to provide clinical benefit at doses that may not 
induce hemodynamic changes or long atIer tolerance to the 
hcmodynamic effects of nitroglycerin have developed. Thus, 
the beneficial effects of exagenously administered nitmglyc- 
erin in the acute ischemic coronary syndromes (18). where 
platelet-thrombos formation may play an important patho- 
physiologic role, may in part be related to this antithrom- 
botic property. 
Both endothelium-derived relaxing factor and nitroglyc- 
erin produce their e5ects by generating nitric oxide (25.26). 
Thus. an important mechanism whereby the endotheliom 
maintains its nonthrombogeaicity ntay involve the endogc- 
noos release of endo:helium.derived relaxing factor by the 
endothelium, similar to what was observed with exogenous 
nitroglycerin in this study. Endothelium-derived relaxing 
factor may contribute to the thromboresistance of the endo- 
[helium by stimulating gttanylatc cyclase and the production 
of cyclic GMP (26). 
thrornbos deposition. However, despite mcthylene blue in- 
hibition of the goanylatc cyclase enzyme, increasing cyclic 
Gti? levels by infusing the 8.bromo cyclic GMP analoguc 
(20) markedly decreased platelet deposition. These findings 
indicate that the infosion of nitroglycerin to produce a 10% 
decrease in mean arterial pressure exerts a significant plate- 
let inhibitxy effect. This beneficial effect of nitrog!yccrin on 
the platelet-vessel wall interaction to decrease mural throm- 
bosis (9) appears to be related to guanylate cyclase stimu!a- 
lion and cyclic GMP formation. 
The dose range of nitroglycerin used in patien:s is er- 
trcmely wide. Dose titration to a predetermined physiologic 
end point, such as a IO% decrease in mean arterial pressure. 
is commonly used in clinical studies to evaluate efficacy (18). 
This end point is sufficient to inhibit whole blood platelet 
aggregation in humans (I I) and exerts a potent antithrorn- 
botic effect in pigs both in viva (9) and, as shown in this 
study, ex viva Thus, in addition to vasodilation, at doses 
used clinically, nitroglycerin exerts significant platelet inhib- 
itory and antithrombotic properties. 
These studies were perforroed in the model of deep 
arterial injury exposing the media, where the thrombogenic 
stimulus is great and a welt anchored mural platelet throm- 
bus develoos (21). This model is analoaous to the notore of 
an atherosclerotic plaque clinically (22) to produce a type 3 
injury. The platelet inhibitory effect of nitroglycerin at 
clinically relevant doses has also been demonstrated in the 
presence of milder vessel injury associated with externally 
constricted coronary arteries and periodic formation and 
dislodgrnent of more labile platelet thromhi (14). However, 
in the presence of mild ve~scl injury not exposing the media 
and without external constrictors. nitroalvccrin did not 
affect the adhesion of a monolayer of plateiets to the vessel 
wall (9). Thus, nitroglycerin affects not only platelet inter- 
actior ‘n vitro at high~c&tccntrations (6-g). b.tt-also platelet- 
vessel wall interaction in vivo at physiologic concentrations. 
Mechanism of action. Earlier studies (6,8) using supra- 
physiologic concentrarions of nitroglycerin in vitro demon- 
strated a platelet inhibitory effect that appeared to be related 
to a prostaglandin mechanism. either by decreasing platelet 
thromboxane A, or increasing prostacyclin production, or 
both. However, lower nitrate concentrations in vitro had no 
effect on prostacyclin production (12). Also, the beneficial 
clinical effects of nitroglycerin in viva do not appear to be 
mediated by the prostaglandin system (13). However, both 
this study and the work of Felts et al. (14) not only confirm 
the antithmmbotic efficacy of nitroglycerin in viva at clini- 
cally relevant concentrations, but also suggest hat this effect 
may be related to cyclic GMP generation. More recently, 
pretreatment with a cyclooxygenase inhibitor such as aspirin 
has been shown to potentiate the antiplatelet effect of 
nitroglycerin (23). probably by inhibiting platelets at two 
different ievels. These recent studies raise the possibility 
that nitroglycerin may have a dual mechanism of action on 
platelets. At high concentration and in the absence of blood 
xssels, nitroglycerin may inhibit in vitro plaieht aggrega- 
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